ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 17 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	232.83
AAUM (in Rs. Cr):	233.56
% of top 5 holdings:	36.50%
% of top 10 holdings:	55.31%
No. of scrips:	40

Standard Deviation^:	15.66%
Beta^:	0.90
*Sharpe Ratio^:**	0.85
Average P/B	9.50
Average P/E	49.22
Portfolio Turnover Ratio	0.53
^Computed for the 3-yr period ended October 31, 2025. Based on monthly return. * Risk free rate: 5.69 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	16.3029	17.6717
IDCW:	16.3029	17.6717

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.30
Capital Goods	1.05
Standard Glass Lining Technology Ltd	1.05
Chemicals	2.87
Sumitomo Chemical India Limited	1.35
Linde India Limited	0.81
UPL Limited	0.72
Financial Services	1.25
SBI Life Insurance Company Limited	1.25
Healthcare	93.14
Sun Pharmaceutical Industries Limited	10.96
Divi's Laboratories Limited	8.97
Apollo Hospitals Enterprise Limited	6.35
Max Healthcare Institute Limited	5.71
Torrent Pharmaceuticals Limited	4.51
Cohance Lifesciences Limited	4.43
Fortis Healthcare Limited	3.98
Aurobindo Pharma Limited	3.70
Aster DM Healthcare Limited	3.62
Cipla Limited	3.07
Lupin Limited	3.04
Alkem Laboratories Limited	2.95
Neuland Laboratories Limited	2.82
Dr. Reddy's Laboratories Limited	2.57
Wockhardt Limited	2.27
Abbott India Limited	2.20
Healthcare Global Enterprises Limited	1.77
Glenmark Pharmaceuticals Limited	1.73
Laurus Labs Limited	1.69
Sai Life Sciences Limited	1.53
FDC Limited	1.40
IPCA Laboratories Limited	1.23
Mankind Pharma Limited	1.22
Biocon Limited	1.21
Onesource Specialty Pharma Limited	1.19
Rainbow Childrens Medicare Limited	1.19
Orchid Pharma Limited	1.13
Piramal Pharma Limited	1.13
GlaxoSmithKline Pharmaceuticals Limited	0.99
Poly Medicure Limited	0.93
Caplin Point Laboratories Limited	0.86
Supriya Lifescience Limited	0.85
Shilpa Medicare Limited	0.75
Zydus Lifesciences Limited	0.70
Syngene International Limited	0.48
Short Term Debt & Net Current Assets	1.70

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	-4.07%	2.45%	7.59%	9,593	10,245	10,759
Last 3 Years	18.84%	21.25%	13.90%	16,793	17,835	14,781
Since Inception	13.06%	15.07%	10.60%	16,303	17,486	14,935
Direct - Growth
Last 1 Year	-2.24%	2.45%	7.59%	9,776	10,245	10,759
Last 3 Years	21.18%	21.25%	13.90%	17,803	17,835	14,781
Since Inception	15.38%	15.07%	10.60%	17,672	17,486	14,935

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 5 years period has not been provided, since scheme is in existence for less than 5 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. ITI Pharma & Healthcare Fund NAV as on October 31, 2025: Rs. 16.3029 (Regular Growth Option), Rs. 17.6717 (Direct Growth Option)

Period	Amount Invested	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Fund Value ()	Benchmark Value ()	Additional Benchmark Value ()
Regular - Growth
Last 1 Year	1,20,000	2.05%	8.87%	14.55%	1,21,318	1,25,657	1,29,199
Last 3 Years	3,60,000	17.52%	20.88%	13.57%	4,66,166	4,88,630	4,40,594
Since Inception	4,80,000	17.17%	19.74%	13.54%	6,74,290	7,08,328	6,28,639
Direct - Growth
Last 1 Year	1,20,000	3.98%	8.87%	14.55%	1,22,555	1,25,657	1,29,199
Last3 Years	3,60,000	19.88%	20.88%	13.57%	4,81,884	4,88,630	4,40,594
Since Inception	4,80,000	19.50%	19.74%	13.54%	7,05,140	7,08,328	6,28,639

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).